Regentis Biomaterials Ltd. Announces Pricing of Initial Public Offering

Rhea-AI Summary

Regentis Biomaterials (NYSE American: RGNT) priced its initial public offering of 1,250,000 ordinary shares at $8.00 per share, for aggregate gross proceeds of $10,000,000, with a 45-day underwriter option to purchase up to an additional 187,500 shares. The Ordinary Shares are expected to begin trading on December 4, 2025, and the Offering is expected to close on or about December 5, 2025, subject to customary closing conditions.

The company intends to use net proceeds primarily for development activities, including completing its pivotal trial and preparing the PMA submission for GerlinC, and for corporate purposes including repayment of certain debt and deferred compensation. ThinkEquity is sole book-running manager.

Positive

• Gross proceeds of $10.0M from the IPO
• Proceeds earmarked for pivotal trial completion and PMA preparation
• Listing expected on NYSE American on Dec 4, 2025

Negative

• Underwriters have a 45-day option for up to 187,500 shares (potential dilution)
• Proceeds stated before underwriting discounts and offering expenses

Key Figures

IPO price: $8.00 per share Base shares offered: 1,250,000 shares Gross proceeds: $10,000,000 +5 more

8 metrics

IPO price $8.00 per share Initial public offering price for Ordinary Shares

Base shares offered 1,250,000 shares Ordinary Shares in the IPO Offering

Gross proceeds $10,000,000 Aggregate gross proceeds before discounts and expenses

Over-allotment option 187,500 shares Additional Ordinary Shares available to underwriters

Over-allotment period 45 days Duration of underwriters’ option to purchase extra shares

Effective date November 12, 2025 Form F-1 registration statement became effective

Form F-1 file number 333-285692 SEC registration statement for the Offering

Trading start date December 4, 2025 Expected start of trading on NYSE American under RGNT

Market Reality Check

Price: $6.88 Vol: Volume 3,931 is at 0.04x ...

low vol

$6.88 Last Close

Volume Volume 3,931 is at 0.04x the 20-day average of 87,709 shares. low

Technical Price $7.14 is trading below the 200-day MA of $7.38, near the 52-week range.

Historical Context

1 past event · Latest: Dec 05 (Neutral)

Pattern 1 events

Date	Event	Sentiment	Move	Catalyst
Dec 05	IPO closing	Neutral	-2.1%	Closing of IPO and start of trading on NYSE American.

Pattern Detected

Limited history shows a modest negative move following the IPO closing announcement.

Recent Company History

Recent news for RGNT centers on its NYSE American listing and capital raise. On Dec 05, 2025, the company announced the closing of its IPO of 1,250,000 shares at $8.00 per share for gross proceeds of $10,000,000, with a 45-day option for 187,500 additional shares. The stock moved -2.14% over the following 24 hours. Today’s pricing announcement reflects the same IPO terms and intended use of proceeds.

Market Pulse Summary

This announcement detailed the IPO pricing at $8.00 per share for 1,250,000 Ordinary Shares, for gro...

Analysis

This announcement detailed the IPO pricing at $8.00 per share for 1,250,000 Ordinary Shares, for gross proceeds of $10,000,000, plus an over-allotment option of 187,500 shares. The company plans to direct proceeds toward completing its pivotal trial, preparing the PMA submission for GerlinC, and corporate uses such as debt and deferred compensation repayment. Investors may track trial milestones, PMA progress, and subsequent financing needs.

Key Terms

initial public offering, underwriters, over-allotments, pma submission, +2 more

6 terms

initial public offering financial

"announced the pricing of its initial public offering (the “Offering”)"

An initial public offering (IPO) is when a private company first sells its shares to the public and becomes a stock-listed company. It matters because it allows the company to raise money from a wide range of investors, helping it grow, while giving early shareholders a way to sell some of their ownership.

underwriters financial

"granted the underwriters a 45-day option to purchase up to"

Underwriters are financial professionals or institutions that help companies raise money by selling new securities, such as stocks or bonds, to investors. They assess the risk and determine the price at which these securities should be sold, acting like a bridge between the company and the investors. Their role helps ensure that the company raises the needed funds while providing investors with options that reflect the level of risk involved.

over-allotments financial

"option to purchase up to an additional 187,500 Ordinary Shares to cover over-allotments"

An over-allotment is a temporary extra batch of shares that the underwriters of a stock offering are allowed to sell beyond the original amount, with the right to buy those shares back later. Think of it as spare tickets sold to meet demand and then reclaimed if needed to keep the market orderly; it helps stabilize the stock price after an offering and can affect short-term supply and potential dilution, which matters to investors tracking price and ownership stakes.

pma submission regulatory

"completion of its pivotal trial, and preparation of the PMA submission for GerlinC"

A PMA submission is a formal application to the U.S. Food and Drug Administration seeking premarket approval for a high‑risk medical device by providing detailed safety and effectiveness evidence. For investors, PMA approval is a gatekeeper to commercial sales in the U.S.; receiving it can unlock significant revenue while delays, additional data requests, or rejection can push back market entry and increase development costs — think of it like applying for a very strict license to sell a new kind of vehicle.

form f-1 regulatory

"A Registration Statement on Form F-1 (File No. 333-285692)"

A Form F-1 is the document a non-U.S. company files with U.S. regulators when it wants to sell stock or other securities to U.S. investors. It lays out the company’s business, finances, risks and how the offering will work, acting like a product manual and ingredient list so investors can judge what they’re buying. For investors, it’s a key source of verified information used to compare opportunities and assess potential reward and risk.

prospectus regulatory

"The Offering is being made only by means of a prospectus."

A prospectus is a detailed document that explains a company's plans for offering new shares or investments to the public. It’s important because it provides potential investors with key information about the company’s business, risks, and how they might make money, helping them decide whether to invest. Think of it as a guidebook for understanding what you're buying into.

AI-generated analysis. Not financial advice.

Herzliya, Israel, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Regentis Biomaterials Ltd. (NYSE American: RGNT) (“Regentis”, or the “Company”), a regenerative medicine company dedicated to developing innovative tissue repair solutions that seek to restore the health and enhance the quality of life of patients, today announced the pricing of its initial public offering (the “Offering”) of 1,250,000 ordinary shares (“Ordinary Shares”) at an initial public offering price of $8.00 per Ordinary Share, for aggregate gross proceeds of $10,000,000 before deducting underwriting discounts and estimated offering expenses payable by the Company. In addition, the Company has granted the underwriters a 45-day option to purchase up to an additional 187,500 Ordinary Shares to cover over-allotments, if any.

The Ordinary Shares are expected to begin trading on the NYSE American LLC on December 4, 2025, under the symbol “RGNT”. The Offering is expected to close on or about December 5, 2025, subject to satisfaction of customary closing conditions.

The Company intends to use the net proceeds from the Offering primarily for development activities, including the completion of its pivotal trial, and preparation of the PMA submission for GerlinC, and also for corporate purposes including the repayment of certain debt and deferred compensation payments.

ThinkEquity is acting as sole book-running manager for the Offering.

A Registration Statement on Form F-1 (File No. 333-285692) and amendments thereto relating to the Ordinary Shares being sold in the Offering was filed with the U.S. Securities and Exchange Commission (“SEC”) and became effective, as amended, on November 12, 2025. The Offering is being made only by means of a prospectus. Copies of the preliminary prospectus and the final prospectus, when available, may be obtained from ThinkEquity, 17 State Street, 41^st Floor, New York, New York 10004.  The preliminary prospectus was filed with the SEC and is available, and the final prospectus will be filed with the SEC and will be available on the SEC’s website located at http://www.sec.gov.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Regentis Biomaterials Ltd.

Regentis Biomaterials Ltd. is a regenerative medicine company dedicated to developing innovative tissue repair solutions that seek to restore the health and enhance the quality of life of patients. The Company’s current efforts are focused on orthopedic treatments using its Gelrin platform based on degradable hydrogel implants to regenerate damaged or diseased tissue. GelrinC is Regentis’ cartilage injury therapeutic based on a unique hydrogel, erodible and resorbable, matrix of polyethylene glycol. The Company’s lead product candidate, GelrinC, is a cell-free, off-the-shelf hydrogel that is cured into a temporary implant in the knee for the treatment of painful injuries to articular knee cartilage. GelrinC was approved as a device with a Conformité Européene mark in Europe, (CE mark number 3900600CE02). The Company plans to start commercialization efforts in Europe to bring its product to market, while being focused in parallel on completing its pivotal study for obtaining United States Food and Drug Administration approval. For more information, please visit https://www.regentis.co.il/

Forward Looking Statements

This press release contains “forward-looking statements” that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” "will” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words, and include the expected start of trading of the Ordinary Shares on the NYSE American LLC, the expected use of proceeds, and the expected date of closing of the Offering. Forward-looking statements are based on Regentis’ current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. For a more detailed description of the risks and uncertainties affecting Regentis, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission (“SEC”), including, but not limited to, the risks detailed in the section titled “Risk Factors” in the final prospectus related to the public offering filed with the SEC. Forward-looking statements contained in this announcement are made as of this date, and Regentis undertakes no duty to update such information except as required under applicable law.

For Investor Relations Inquiries

Arie Gordashnikov
arie@shimony.com
+972-3-6116629

FAQ

When will Regentis Biomaterials (RGNT) begin trading on the NYSE American?

The Ordinary Shares are expected to begin trading on December 4, 2025 under the symbol RGNT.

How many shares did Regentis (RGNT) offer and at what price?

Regentis offered 1,250,000 ordinary shares at $8.00 per share, totaling $10,000,000 gross.

What will Regentis (RGNT) use the IPO proceeds for?

Net proceeds will be used primarily to complete the pivotal trial, prepare the PMA submission for GerlinC, and for corporate purposes including debt repayment.

Is there a potential for additional shares after the RGNT IPO?

Yes, underwriters were granted a 45-day option to purchase up to 187,500 additional shares to cover over-allotments.

When is the RGNT offering expected to close?

The Offering is expected to close on or about December 5, 2025, subject to customary closing conditions.